Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 32.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.17% |
| Dec 31, 2025 | 41.34% |
| Sep 30, 2025 | -8.65% |
| Jun 30, 2025 | 9.53% |
| Mar 31, 2025 | 28.85% |
| Dec 31, 2024 | 24.54% |
| Sep 30, 2024 | -30.85% |
| Jun 30, 2024 | -7.42% |
| Mar 31, 2024 | -2.05% |
| Dec 31, 2023 | -321.76% |
| Sep 30, 2023 | 85.91% |
| Jun 30, 2023 | -28.61% |
| Mar 31, 2023 | -35.68% |
| Dec 31, 2022 | 17.89% |
| Sep 30, 2022 | 62.90% |
| Jun 30, 2022 | -50.38% |
| Mar 31, 2022 | -43.09% |
| Dec 31, 2021 | -66.44% |
| Sep 30, 2021 | 114.53% |
| Jun 30, 2021 | 132.60% |